PDGFRA and glioblastoma: No activity in GBM, promising with everolimus (14, 51)Risk of intratumoral hemorrhage (55)Specific to PDGFRA, in clinical trials (53, 54)No significant improvement in clinical trial (56)No significant antitumor activity (57)Phase II GBM trial, no survival change (58)Phase II GBM trial, failed first endpoint (59)Phase II GBM trial, closed after interim analysis (60)